CHGA and plasma cell myeloma: Dex-Spi combination treatment also gave rise to a differential transcriptomic and proteomic signature (C; Fig. 7J) that can help explain the enhanced Dex-induced myeloma cell killing in combination with Spi (D; Fig. 7J).